SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G/A

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(AMENDMENT 1)

VERTEX PHARMACEUTICALS INCORPORATED

(NAME OF ISSUER)

COMMON STOCK

(Title of Class of Securities)

92532F100

(CUSIP Number)

DECEMBER 31,2002

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

X Rule 13d-1 (b)

Rule 13d-1 (c)

Rule 13d-1 (d)

CUSIP No. 92532F100

1. Names of reporting persons J.P.Morgan Chase & Co.

13-2624428

Page 1 of 3 pages

13G/A

| | | MBER OF A GROUP* | (a) (b) | | | | |
|-----------------------|--|---|---|---|--|--|--|
| NSHIP OR PLACE | OF ORGAN | | | | | | |
| | OF ORGAN | | 3. SEC USE ONLY | | | | |
| | | IZATION | | | | | |
|)F | 5. | SOLE VOTING POWER | 1,969,930 | | | | |
| LLY Y | 6. | SHARED VOTING POWER | 59,916 | | | | |
| IG | 7. | SOLE DISPOSITIVE POWER | 2,188,950 | | | | |
| ТТН | 8. | SHARED DISPOSITIVE POWER | 108,716 | | | | |
| 6 OX IF THE AGGREG | | | RSON | | | | |
| | RESENTED I | BY AMOUNT IN ROW (9) | | | | | |
| F REPORTING PE | RSON* | HC | | | | | |
| VERTEX PHARMAC | CEUTICALS suer's Pri TREET | incipal Executive Offices: | | | | | |
| | Y NG TH ATE AMOUNT BENN ATE AMOUNT BENN ON IF THE AGGREG SOX IF TH | Y T O T T T T T T T T T T T T T T T T T | Y 7. SOLE DISPOSITIVE POWER NG ITH 8. SHARED DISPOSITIVE POWER ATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PE 6 IOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES 1 SHARES IT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) F REPORTING PERSON* HC Name of Issuer: VERTEX PHARMACEUTICALS INCORPORATED Address of Issuer's Principal Executive Offices: | Y T. SOLE DISPOSITIVE POWER 2,188,950 G TH 8. SHARED DISPOSITIVE POWER 108,716 ATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON G OX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES SHARES T OF CLASS REPRESENTED BY AMOUNT IN ROW (9) F REPORTING PERSON* HC Name of Issuer: VERTEX PHARMACEUTICALS INCORPORATED Address of Issuer's Principal Executive Offices: | | | |

- Item 2(a). Name of Person Filing: J.P. MORGAN CHASE & CO.
- Item 2(b). Address of Principal Business Office or, if None, Residence: 270 PARK AVE NEW YORK, NY 10017
- Item 2(c). Citizenship Delaware
- Item 2(d). Title of Class of Securities: COMMON STOCK Unless otherwise noted, security being reported is common stock

Item 2(e). CUSIP Number: 92532F100

Item 3 If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) Or (c), Check Whether the Person Filing is a :

- (a) Broker or dealer registered under Section 15 of the Exchange Act;
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act;
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act;
- (d) Investment company registered under Section 8 of the Investment Company Act;
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
 (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an Investment company under Section 3(c)(14) of the Investment Company act;
- (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(b), check this box.

Х

Page 2 of 3 pages

Item 4. Ownership

Provide the following information regarding the aggregate number and Percentage of the class of securities of issuer identified in Item 1. (a) Amount beneficially owned: 2,297,666 Including 0 shares where there is a Right to Acquire.

- (b) Percent of class: 3.0%
- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote: 1,969,930
 - (ii) Shared power to vote or to direct the vote: 59,916
 - (iii) Sole power to dispose or to direct the disposition of: 2,188,950
 - (iv) Shared power to dispose or to direct the disposition of: 108,716

Item 5. Ownership of Five Percent or Less of a Class. YES

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. (X)

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

J.P. Morgan Chase & Co. is the beneficial owner of 2,297,666 shares of the issuer's common stock on behalf of other persons known to have one or more of the following:

the right to receive dividends for such securities; the power to direct the receipt of dividends from such securities; the right to receive the proceeds from the sale of such securities; the right to direct the receipt of proceeds from the sale of such securities;

No such person is known to have an interest in more than 5% of the class of securities reported herein unless such person is identified below.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security being reported on by the Parent Holding Company.
This notice is filed on behalf of J.P. Morgan Chase & Co. and its wholly owned
Subsidiaries, JPMorgan Chase Bank; J.P. Morgan Fleming Asset Management (US
A) Inc.; J.P. Morgan Investment Management Inc.

Item 8.Identification and Classification of Members of the Group.Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 3 of 3 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: FEBRUARY 13,2003

J.P. Morgan Chase & Co. By: /s/ Margaret R. Rubin

> Margaret R. Rubin Corporate Compliance

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the commission may be incorporated by reference. The name and any title of each person who signs the the statement shall be typed or printed beneath his signature.